A clinical trial has shown that semaglutide safely reduces liver fat levels by 31% in people living with HIV who have liver disease. The findings suggest that the drug is a safe and effective therapy. The results were presented at the Conference on Retroviruses and Opportunistic Infections 2024 (CROI) in Denver.
Patients also experienced improvements in weight, blood sugar and triglyceride levels, indicating the broader therapeutic potential of semaglutide. Additional studies are underway to see if any unique changes in immunological or inflammatory pathways occur with this medication.
This drug can be used to treat HIV and liver disease, which represents a significant advance in medicine, and could also be a useful tool in combating the negative effects of HIV, which have a significant impact on people’s wellbeing.